Pro­to­cols: Cell Med­ica strikes a TCR re­search deal with Uni­ver­si­ty Col­lege Lon­don; UK of­fers ear­ly ac­cess to Ab­b­Vie's vene­to­clax

A few months af­ter strik­ing a CAR-T pact with Bay­lor, Cell Med­ica has struck a deal to work with Uni­ver­si­ty Col­lege Lon­don on new T cell re­cep­tor prod­ucts. The biotech was drawn to the work of Pro­fes­sor Hans Stauss and Pro­fes­sor Em­ma Mor­ris of UCL. TCRs are at­trac­tive to drug de­vel­op­ers be­cause they of­fer a new range of in­tra­cel­lu­lar tar­gets to add to the sur­face tar­gets al­ready in sight. New deals around cell ther­a­pies have ex­plod­ed in re­cent times, and aca­d­e­m­ic re­searchers have been thrust in­to the mid­dle of the fray.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER